Naci H - Search Results

1

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Davis C, et al. Among authors: naci h. BMJ. 2017 Oct 4;359:j4530. doi: 10.1136/bmj.j4530. BMJ. 2017. PMID: 28978555 Free PMC article.

2

Evidence of comparative efficacy should have a formal role in European drug approvals.

Sorenson C, Naci H, Cylus J, Mossialos E. Sorenson C, et al. Among authors: naci h. BMJ. 2011 Sep 6;343:d4849. doi: 10.1136/bmj.d4849. BMJ. 2011. PMID: 21896610 No abstract available.

3

Raising the bar for market authorisation of new drugs.

Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Naci H, et al. BMJ. 2012 Aug 7;345:e4261. doi: 10.1136/bmj.e4261. BMJ. 2012. PMID: 22872693 No abstract available.

4

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.

Naci H, Ioannidis JP. Naci H, et al. BMJ. 2013 Oct 1;347:f5577. doi: 10.1136/bmj.f5577. BMJ. 2013. PMID: 24473061 Free PMC article. Review.

5

Rethinking the appraisal and approval of drugs for type 2 diabetes.

Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS. Naci H, et al. BMJ. 2015 Oct 9;351:h5260. doi: 10.1136/bmj.h5260. BMJ. 2015. PMID: 26452524 Review. No abstract available.

6

Why the drug development pipeline is not delivering better medicines.

Naci H, Carter AW, Mossialos E. Naci H, et al. BMJ. 2015 Oct 23;351:h5542. doi: 10.1136/bmj.h5542. BMJ. 2015. PMID: 26496934 Free article. No abstract available.

7

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Naci H, Smalley KR, Kesselheim AS. Naci H, et al. JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415. JAMA. 2017. PMID: 28810023 Free PMC article.

8

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Naci H, Davis C, Savović J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, Booth CM. Naci H, et al. BMJ. 2019 Sep 18;366:l5221. doi: 10.1136/bmj.l5221. BMJ. 2019. PMID: 31533922 Free PMC article.

9

Inappropriate use of progression-free survival in cancer drug approvals.

Naci H, Davis C. Naci H, et al. BMJ. 2020 Mar 10;368:m770. doi: 10.1136/bmj.m770. BMJ. 2020. PMID: 32156802 No abstract available.

10

Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.

Pinto A, Naci H, Neez E, Mossialos E. Pinto A, et al. Among authors: naci h. Value Health. 2020 Mar;23(3):319-327. doi: 10.1016/j.jval.2019.10.010. Epub 2020 Jan 13. Value Health. 2020. PMID: 32197727 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters